Objective: To analyze various immune cytokines (NKG2D, IL-12, IL-15, IL-18, DC cells, TNF-a, IFN-r) and peripheral blood of patients with non-small cell lung cancer (NSCLC) at different times after chemotherapy. Changes in CD4+, CD8+, Th17 and IgG, IgM, and IgA levels. Methods: A total of 118 NSCLC patients who attended the Oncology Department of the Affiliated Hospital of Chengde Medical College from September 2018 to September 2021 were selected as the research objects, and the patients were analyzed at different time points (before chemotherapy, after the first chemotherapy, and after the second chemotherapy). The effects of NKG2D, IL-12, IL-15, IL-18, DC cells, TNF-A, IFN-r, CD4+, CD8+ Th17, IgG, IgM and IgA levels in peripheral blood at different time points (before chemotherapy, after the first chemotherapy and after the second chemotherapy) were analyzed. The changes of NKG2D, IL-12, IL-15, IL-18, DC cells, TNF-A, IFN-r and the levels of CD4+, CD8+ Th17, IgG, IgM and IgA in peripheral blood were compared at each time point. Results: NKG2D, IL-12, IL-15, IL-18, TNF-a, IFN-r gradually decreased before chemotherapy, one week after chemotherapy, and two weeks after chemotherapy, the difference was statistically significant, but DC cells were not significant Variety. CD4+ and CD8+ both increased significantly, and the levels of Th17, IgG, IgM, and IgA gradually decreased. Conclusion: In the course of chemotherapy, all immune factors except DC cells were significantly decreased compared with those before chemotherapy, and the decrease of immune factors except DC cells was positively correlated with the length of chemotherapy cycle. If additional immunotherapy is needed, it should be carried out in the early stage of chemotherapy.
Lin, Y., Xu, J. and Lan, H. (2019) Tumor-Associated Macrophages in Tumor Metastasis: Biological Roles and Clinical Therapeutic Applications. Journal of Hematology & Oncology, 12, 1-16. https://doi.org/10.1186/s13045-019-0760-3
[3]
Binnewies, M., Roberts, E.W., Kersten, K., et al. (2018) Understanding the Tumor Immune Microenvironment (TIME) for Effective Therapy. Nature Medicine, 24, 541-550. https://doi.org/10.1038/s41591-018-0014-x
[4]
Kumar, S., Kumar, A., Samet, B., et al. (2020) A Chaos Study of Tumor and Effector Cells in Fractional Tumor-Immune Model for Cancer Treatment. Chaos, Solitons & Fractals, 141, Article ID: 110321. https://doi.org/10.1016/j.chaos.2020.110321
[5]
Rotow, J. and Bivona, T.G. (2017) Understanding and Targeting Resistance Mechanisms in NSCLC. Nature Reviews Cancer, 17, 637. https://doi.org/10.1038/nrc.2017.84
[6]
Socinski, M.A., Jotte, R.M., Cappuzzo, F., et al. (2018) Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC. New England Journal of Medicine, 378, 2288-2301. https://doi.org/10.1056/NEJMoa1716948
[7]
Antonia, S.J., Villegas, A., Daniel, D., et al. (2018) Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC. New England Journal of Medicine, 379, 2342-2350. https://doi.org/10.1056/NEJMoa1809697
[8]
Wang, J. and Li, H. (2018) CircRNA circ_0067934 Silencing Inhibits the Proliferation, Migration and Invasion of NSCLC Cells and Correlates with Unfavorable Prognosis in NSCLC. European Review for Medical and Pharmacological Sciences, 22, 3053-3060.
[9]
Ramalingam, S.S., Vansteenkiste, J., Planchard, D., et al. (2020) Overall Survival with Osimertinib in Untreated, EGFR-Mutated Advanced NSCLC. New England Journal of Medicine, 382, 41-50. https://doi.org/10.1056/NEJMoa1913662
[10]
Gray, J.E., Villegas, A., Daniel, D., et al. (2020) Three-Year Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC—Update from PACIFIC. Journal of Thoracic Oncology, 15, 288-293. https://doi.org/10.1016/j.jtho.2019.10.002
[11]
Dhar, P. and Wu, J.D. (2018) NKG2D and Its Ligands in Cancer. Current Opinion in Immunology, 51, 55-61. https://doi.org/10.1016/j.coi.2018.02.004
[12]
Liu, H., Wang, S., Xin, J., et al. (2019) Role of NKG2D and Its Ligands in Cancer Immunotherapy. American Journal of Cancer Research, 9, 2064.
[13]
Wensveen, F.M., Jelenčić, V. and Polić, B. (2018) NKG2D: A Master Regulator of Immune Cell Responsiveness. Frontiers in Immunology, 9, 441. https://doi.org/10.3389/fimmu.2018.00441
[14]
Lusty, E., Poznanski, S.M., Kwofie, K., et al. (2017) IL-18/IL-15/IL-12 Synergy Induces Elevated and Prolonged IFN-γ Production by ex Vivo Expanded NK Cells Which Is Not Due to Enhanced STAT4 Activation. Molecular Immunology, 88, 138-147. https://doi.org/10.1016/j.molimm.2017.06.025
[15]
Kundu, M., Roy, A. and Pahan, K. (2017) Selective Neutralization of IL-12 p40 Monomer Induces Death in Prostate Cancer Cells via IL-12–IFN-γ. Proceedings of the National Academy of Sciences, 114, 11482-11487. https://doi.org/10.1073/pnas.1705536114
[16]
Eisenbarth, S.C. (2019) Dendritic Cell Subsets in T Cell Programming: Location Dictates Function. Nature Reviews Immunology, 19, 89-103. https://doi.org/10.1038/s41577-018-0088-1
[17]
Pemmaraju, N., Lane, A.A., Sweet, K.L., et al. (2019) Tagraxofusp in Blastic Plasmacytoid Dendritic-Cell Neoplasm. New England Journal of Medicine, 380, 1628-1637. https://doi.org/10.1056/NEJMoa1815105
Mojic, M., Takeda, K. and Hayakawa, Y. (2018) The Dark Side of IFN-γ: Its Role in Promoting Cancer Immunoevasion. International Journal of Molecular Sciences, 19, 89. https://doi.org/10.3390/ijms19010089
